Hemorrhagic stroke accounts for approximately 15% of strokes.
Computed tomography (CT) or magnetic resonance imaging (MRI), with high sensitivity for intracerebral hemorrhage, are essential in diagnosis.
The primary treatment for people with hemorrhagic stroke involves supportive care and optimization of intracranial hemodynamics.
Surgical resection of intracerebral hematomas may be of benefit in select cases, such as cerebellar hematomas >3 cm in diameter causing brain stem compression or hydrocephalus.
Patients treated in dedicated stroke units have improved survival and reduced disability at 1 year.
Stroke is an acute neurologic deficit caused by cerebrovascular etiology. It is further subdivided into ischemic stroke and hemorrhagic stroke.
Hemorrhagic stroke is due to rupture of a cerebrospinal artery, resulting in intraparenchymal, subarachnoid, and intraventricular hemorrhage.
Intracerebral hemorrhage is further subdivided into primary and secondary etiology: primary spontaneous intracerebral hemorrhage is defined as hemorrhage in the absence of vascular malformations or associated diseases; secondary intracerebral hemorrhage is from an identifiable vascular malformation or as a complication of other medical or neurologic diseases that either impair coagulation or promote vascular rupture.
History and exam
- neck stiffness
- history of atrial fibrillation
- history of liver disease
- visual changes
- sudden onset followed by progression
- altered sensation
- sensory loss
- history of hematologic disorder
- altered level of consciousness/coma
- gaze paresis
- advanced age
- male sex
- Asian, black, and/or Hispanic ethnicity
- family history of hemorrhagic stroke
- cerebral amyloid angiopathy
- autosomal dominant mutations in the COL4A1 gene
- hereditary hemorrhagic telangiectasia
- autosomal dominant mutations in the KRIT1, CCM2, or PDCD10 genes
- illicit sympathomimetic drugs
- vascular malformations
- nonsteroidal anti-inflammatory drugs (NSAIDs)
- diabetes mellitus
- heavy alcohol abuse
- cerebral vasculitis
- Moyamoya disease
Fernando D. Goldenberg, MD
Clinical Associate of Neurology
Medical Director, Neuroscience ICU
Director, Neurocritical Care Education
Co-Director, Stroke Center
University of Chicago
FDG declares that he has no competing interests.
Raisa C. Martinez, MD
Department of Neurosciences
Wellstar Health System, Kennestone
RCM declares that she has no competing interests.
Dr Fernando Goldenberg and Dr Raisa Martinez would like to gratefully acknowledge Dr Alejandro Hornik, Dr Eric E. Smith, and Dr T. Dion Fung, the previous contributors to this topic.
EES is an author of a number of references cited in this topic. AH and TDF declare that they have no competing interests.
Louis R. Caplan, MD
Lecturer in Neurology
Beth Israel Deaconess Medical Center
Division of Cerebrovascular/Stroke
LRC declares that he has no competing interests.
Julien Morier, MD
Centre Hospitalier Universitaire Vaudois (CHUV)
JM declares that he has no competing interests.
Use of this content is subject to our disclaimer